NEOGENOMICS INCNEO

NEOGENOMICS INC Segments Disclosure

10-KFiled Feb 17, 20262 min read
Segment Information
The Company operates under a single segment based on an analysis of the Company's reporting structure, the information available to the CODM, and the strategic decisions being made by management. The Company provides services to a diverse client base, which includes community-based pathology and oncology practices, hospital pathology labs, reference labs, academic centers, and pharmaceutical companies. Revenue is derived from clients by providing clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions.
The Company's Chief Executive Officer serves as the Chief Operating Decision Maker. The CODM uses net loss, as reported on the Consolidated Statements of Operations, to monitor budget versus actual results to evaluate profitability and allocate resources. The CODM is regularly provided with financial information, including revenue and expenses, in a format consistent with the Consolidated Statements of Operations. The CODM does not review assets at a different level or category
than those disclosed in the Consolidated Balance Sheets. Substantially all of the Company's revenue and tangible long-lived assets are attributable to the U.S.
The following table presents selected financial information with respect to the Company's single operating segment for the years ended December 31, 2025, 2024, and 2023:
202520242023
Net revenue$727,332 $660,566 $591,643 
Less:
Amortization31,752 33,446 35,133 
Depreciation36,072 39,101 37,450 
Stock-based compensation41,316 33,413 24,633 
Other cost of revenue(1)
379,535 332,252 310,562 
Other general and administrative(1)
205,414 197,775 184,484 
Other research and development(1)
32,544 28,283 25,187 
Other sales and marketing(1)
88,827 81,744 70,842 
Impairment charges27,753 — — 
Restructuring charges— 6,658 11,088 
Loss from operations(115,881)(92,106)(107,736)
Interest income(9,070)(18,427)(16,902)
Interest expense3,753 6,617 6,907 
Other expense (income)(296)379 (644)
Loss before taxes(110,268)(80,675)(97,097)
Income tax benefit(2,243)(1,949)(9,129)
Net loss$(108,025)$(78,726)$(87,968)
(1) Excludes amounts related to amortization, depreciation, and stock-based compensation, as applicable.

Historical Timeline

Fiscal YearFiled
2025Feb 17, 2026Showing above
2024Feb 18, 2025
2023Feb 20, 2024
2022Feb 24, 2023
2019Feb 28, 2020
2018Feb 26, 2019

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesRevenueEarnings Per ShareFair ValuePP&EGoodwill & IntangiblesLeasesDebtCommitmentsNew Standards